Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IVRA vs DAYPRO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ivermectin binds selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased chloride ion influx and hyperpolarization, resulting in paralysis and death of the parasite. It also interacts with gamma-aminobutyric acid (GABA)-gated chloride channels.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and thereby alleviating pain and inflammation.
Onchocerciasis (river blindness),Strongyloidiasis (threadworm infection),Scabies (off-label, FDA-approved for scabies in certain contexts; also used off-label for head lice, pediculosis, and various parasitic infections)
Osteoarthritis,Rheumatoid arthritis
Intravenous 500 mg every 6 hours.
600 mg orally once daily; max 1200 mg/day
Terminal elimination half-life is approximately 12-15 hours in healthy adults; prolonged in hepatic impairment (up to 30 hours) and in elderly patients.
Approximately 40-70 hours (mean ~50 h), allowing once-daily dosing; steady-state reached in 4-6 days.
Primarily metabolized by CYP3A4 in the liver; also a substrate for P-glycoprotein (P-gp) transporter.
Primarily hepatic via CYP2C9; undergoes glucuronidation.
Renal excretion of unchanged drug accounts for approximately 10-20% of elimination; fecal/biliary excretion is the primary route (60-70% as metabolites, primarily unchanged drug via bile).
Renal (approx. 70-80% as unchanged drug and glucuronide conjugate; biliary/fecal excretion accounts for the remainder).
Approximately 85-90% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
>99% bound primarily to albumin.
0.6-0.8 L/kg, indicating distribution into total body water with some extravascular binding; increased in heart failure or severe hepatic disease.
0.15-0.2 L/kg; indicates limited extravascular distribution mainly in plasma and extracellular fluid.
Oral: 70-80% (extensive first-pass metabolism reduces from 90% absorbed); Intravenous: 100%.
Oral: approximately 80-90%.
GFR >60 m L/min: 500 mg q6h; GFR 30-60: 250 mg q6h; GFR 15-30: 250 mg q12h; GFR <15: 250 mg q24h.
Cr Cl 30-59 m L/min: 600 mg once daily; Cr Cl <30 m L/min: 400 mg once daily; hemodialysis: 400 mg once daily after dialysis
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg q6h; Child-Pugh C: 250 mg q12h.
Child-Pugh Class A: no adjustment; Class B: 400 mg once daily; Class C: avoid use
10 mg/kg IV every 6 hours; maximum 500 mg per dose.
Not approved for pediatric use
Same as adult; monitor renal function and adjust per GFR.
Initiate at 400 mg once daily; max 600 mg once daily; monitor renal function
None.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. DAYPRO is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
Potential for severe adverse reactions (Mazzotti reaction) in onchocerciasis patients; neurotoxicity (especially in elderly or patients with high drug levels); avoid use in patients with impaired hepatic function; caution with concomitant use of CNS depressants; not recommended in pregnancy (Category C).
Cardiovascular risk, gastrointestinal bleeding and ulceration, renal toxicity, hypertension, anaphylactoid reactions, serious skin reactions, hematologic toxicity (anemia), hepatic effects, asthma exacerbation, fluid retention, and use in pregnancy (avoid in late pregnancy).
Hypersensitivity to ivermectin or any component of the formulation; not for use in pediatric patients weighing less than 15 kg for scabies treatment (due to risk of neurotoxicity).
Aspirin allergy, history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs, perioperative pain in the setting of CABG surgery, advanced renal disease, and pregnancy (third trimester).
No food interactions with IVRA technique; however, lidocaine administration may be affected by grapefruit juice (inhibits metabolism) — avoid grapefruit juice before procedure.
No significant food interactions. However, taking with food or antacids can reduce GI irritation. Avoid alcohol to minimize risk of gastric mucosal injury.
IVRA is contraindicated in pregnancy. First trimester: high risk of major congenital malformations (neural tube defects, cleft palate). Second and third trimesters: risk of fetal nephrotoxicity, oligohydramnios, and premature ductus arteriosus closure.
Daypro (oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID) with teratogenic potential. First trimester: Avoid; associated with increased risk of miscarriage and cardiac defects. Second trimester: Use only if clearly needed; possible oligohydramnios and fetal renal impairment. Third trimester: Contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal pulmonary hypertension.
Excreted into breast milk in low amounts; M/P ratio 0.3. Avoid use due to potential adverse effects in nursing infants (renal impairment, bleeding).
Oxaprozin is excreted into breast milk in low concentrations (M/P ratio approximately 0.1-0.3). Due to potential adverse effects on infant renal function and platelet function, caution is advised. Avoid long-term use; short-term use with infant monitoring recommended.
No dose adjustment is recommended as IVRA is contraindicated. In case of inadvertent use in pregnancy, discontinue immediately.
No specific dose adjustments established; however, pharmacokinetic changes in pregnancy (increased volume of distribution, altered hepatic metabolism) may require dose titration based on clinical response. Use lowest effective dose for shortest duration. Avoid in third trimester.
IVRA (intravenous regional anesthesia) is not a drug but a technique. For Bier block using lidocaine, use 0.5% preservative-free lidocaine, 3 mg/kg for upper extremity. Avoid in patients with sickle cell disease or severe hypertension. Monitor for tourniquet pain after 30 minutes; deflate tourniquet gradually to prevent systemic toxicity.
Daypro (oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID) with a long half-life (~50-60 hours) allowing once-daily dosing. Use with caution in elderly or renal impairment due to reduced clearance. Monitor renal function, hepatic enzymes, and signs of GI bleeding. Avoid use with other NSAIDs or aspirin. May increase lithium, methotrexate, and warfarin levels.
You will receive local anesthetic injected into a vein in your arm after a tourniquet is applied.,The tourniquet will be kept inflated during the procedure to keep the medication in the arm.,You may feel a burning sensation when the medication is injected, which is normal.,Do not remove the tourniquet yourself; it will be deflated slowly by the doctor to prevent side effects.,Report any chest discomfort, ringing in ears, or metallic taste immediately.
Take with food or milk to reduce stomach upset.,Swallow tablets whole; do not crush or chew.,Avoid alcohol while taking this medication.,Report signs of bleeding (black/tarry stools, unusual bruising), weight gain, or edema.,Do not take with other NSAIDs or over-the-counter pain relievers without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IVRA vs DAYPRO, answered by our medical review team.
IVRA is a Nonsteroidal Anti-Inflammatory Drug (NSAID) that works by Ivermectin binds selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased chloride ion influx and hyperpolarization, resulting in paralysis and death of the parasite. It also interacts with gamma-aminobutyric acid (GABA)-gated chloride channels.. DAYPRO is a Nonsteroidal Anti-Inflammatory Drug (NSAID) that works by Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and thereby alleviating pain and inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IVRA and DAYPRO depend on the specific clinical indication. These are both Nonsteroidal Anti-Inflammatory Drug (NSAID) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IVRA is: Intravenous 500 mg every 6 hours.. The standard adult dose of DAYPRO is: 600 mg orally once daily; max 1200 mg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IVRA and DAYPRO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IVRA is classified as Category C. IVRA is contraindicated in pregnancy. First trimester: high risk of major congenital malformations (neural tube defects, cleft palate). Second and third trimesters: risk of fetal n. DAYPRO is classified as Category C. Daypro (oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID) with teratogenic potential. First trimester: Avoid; associated with increased risk of miscarriage and cardiac de. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.